Mainz Biomed (MYNZ) Projected to Post Earnings on Tuesday

Mainz Biomed (NASDAQ:MYNZ) will likely be releasing its H2 2025 resultson Tuesday, April 14th. Analysts expect Mainz Biomed to post earnings of ($1.01) per share and revenue of $0.67 million for the quarter. Interested persons may visit the the company’s upcoming H2 2025 earning results page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 7:00 AM ET.

Mainz Biomed Trading Down 4.0%

Shares of MYNZ stock opened at $0.46 on Tuesday. Mainz Biomed has a 1 year low of $0.55 and a 1 year high of $5.34. The firm has a fifty day moving average price of $0.78 and a 200-day moving average price of $1.12. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.52 and a quick ratio of 0.43. The company has a market cap of $4.15 million, a price-to-earnings ratio of -0.01 and a beta of 0.31.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on MYNZ. Weiss Ratings reissued a “sell (e)” rating on shares of Mainz Biomed in a research report on Monday, December 22nd. Maxim Group downgraded shares of Mainz Biomed from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. Finally, Wall Street Zen raised shares of Mainz Biomed to a “hold” rating in a research report on Saturday, December 27th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce”.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Armistice Capital LLC boosted its holdings in Mainz Biomed by 96.5% in the 4th quarter. Armistice Capital LLC now owns 775,263 shares of the company’s stock worth $868,000 after buying an additional 380,744 shares during the period. Steward Partners Investment Advisory LLC boosted its holdings in Mainz Biomed by 200.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 30,000 shares of the company’s stock worth $34,000 after buying an additional 20,000 shares during the period. Finally, Cerity Partners LLC bought a new position in Mainz Biomed in the 4th quarter worth $183,000.

About Mainz Biomed

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.